

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV17243/003001 in an envelope addressed to:

804196914

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on August 16, 2006  
Date

  
Signature

Salena L. Hearne

Typed or printed name of person signing Certificate

Registration Number, if applicable

(713) 228-8600  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Request for Corrected Filing Receipt (2 pages) with attachments  
(4 pages)  
Return Receipt Postcard



8-17-06

1615  
15W

Docket No.: 17243/003001  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Melwyn Abreo et al.

Application No.: 10/566,193

Confirmation No.: 5685

Filed: January 30, 2006

Art Unit: 1615

For: PYRIDYL DERIVATIVES AND THEIR USE  
AS THERAPEUTIC AGENTS

Examiner: Not Yet Assigned

**REQUEST FOR CORRECTED FILING RECEIPT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the above-identified patent application. The official Filing Receipt received by Applicant, a copy of which is attached hereto, has a typographical error in the third Applicant's name. Applicant respectfully requests the third Applicant's name be corrected from "Heins W. Gschwend" to --**Heinz W. Gschwend**-- as shown in the enclosed copy of:

- 1) the second page of the application data sheet which shows the correct spelling of the third Applicant's name;
- 2) the first page of the international publication which shows the correct spelling of the third applicant's name; and
- 3) the pertinent page of the declaration which shows the correct spelling of the third applicant's name.


Applicant additionally requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Applicant believes no fee is due with this request. However, if a fee is due, please charge our Deposit Account No. 50-0591, under Order No. 17243/003001 from which the undersigned is authorized to draw.

Dated: August 16, 2006

Respectfully submitted,

By \_\_\_\_\_  
T. Chyau Liang, Ph.D.  
Registration No.: 48,885  
OSHA · LIANG LLP  
1221 McKinney St., Suite 2800  
Houston, Texas 77010  
(713) 228-8600  
(713) 228-8778 (Fax)



RECEIVED Page 1 of 3

JUN 06 2006

OSHA • LIANG LLP

UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/566,193	01/30/2006	1615	4100	17243/003001		70	8

22511  
OSHA LIANG L.L.P.  
1221 MCKINNEY STREET  
SUITE 2800  
HOUSTON, TX 77010

CONFIRMATION NO. 5685

## FILING RECEIPT



\*OC000000019012991\*

Docketed Action:		
<input checked="" type="checkbox"/> New	<input type="checkbox"/> Previously	<input type="checkbox"/> Non Required
Docket Number: <u>17243/003001</u>		
Attorney Initials: <u>TCH/TCH</u>		
Docketing Initials: <u>NAE</u>		

Date Mailed: 06/01/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Melwyn Abreo, Jamul, CA;  
Daniel F. Harvey, San Diego, CA;  
Heins W. Gschwend, Santa Rosa, CA;  
Wenbao Li, San Diego, CA;  
Chi Tu, San Diego, CA;  
Rajender Kamboj, Burnaby, CANADA;  
Michael D. Winther, Vancouver, CANADA;  
Vishnumurthy Kodumuru, Burnaby, CANADA;  
Cindy J. Hudson, Buena Park, CA;  
Mikhail A. Kondratenko, San Diego, CA;  
Shifeng Liu, Port Coquitlam, CANADA;  
Vandna Raina, Vancouver, CANADA;  
Serguei Sviridov, Burnaby, CANADA;  
Zaihui Zhang, Vancouver, CANADA;  
Mehran Seid Bagherzadeh, North Vancouver, CANADA;  
Shaoyi Sun, Vancouver, CA;

**Power of Attorney:** The patent practitioners associated with Customer Number 22511.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/24657 07/29/2004

## Foreign Applications

UNITED STATES OF AMERICA 60491116 07/30/2003  
UNITED STATES OF AMERICA 60491118 07/30/2003

UNITED STATES OF AMERICA 60491340 07/30/2003  
If Required, Foreign Filing License Granted: 05/30/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/566,193**

Projected Publication Date: 09/07/2006

Non-Publication Request: No

Early Publication Request: No

**Title**

Pyridyl derivatives and their use as therapeutic agents

**Preliminary Class**

514

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

## LICENSE FOR FOREIGN FILING UNDER

**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity  
Given Name:: Daniel  
Middle Name:: F.  
Family Name:: Harvey  
City of Residence:: San Diego  
State or Province of Residence:: CA  
Country of Residence:: US  
Street of mailing address:: 6254 Lakewood Street  
City of mailing address:: San Diego  
State or Province of mailing address:: CA  
Postal or Zip Code of mailing address:: 92122

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity  
Given Name:: Heinz  
Middle Name:: W.  
Family Name:: Gschwend  
City of Residence:: Santa Rosa  
State or Province of Residence:: CA  
Country of Residence:: US  
Street of mailing address:: 161 Meadowcroft Way  
City of mailing address:: Santa Rosa  
State or Province of mailing address:: CA  
Postal or Zip Code of mailing address:: 95403

Applicant Authority Type:: Inventor  
Primary Citizenship Country:: US  
Status:: Full Capacity  
Given Name:: Wenbao

(S7) **Abstract:** Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): wherein: W is -O-, -N(R1)-, C(O), S(O)t ; (where t is 0, 1 or 2), N(R1)S(O)2, S(O)2N(R1), C(O)N(R1) or N(R1)C(O)N(R1); and V is C(O), C(S), C(O)N(R1)-, C(O)O-, S(O)2-, S(O)2N(R1)- or C(R11)H; and x, y, R1, R2, R3, R4, R5, R6, R7, R7a, R8, R8a, R9, R9a, R10 and R10a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.



VIII- 4-1-2-1	Name (LAST, First)	HARVEY, Daniel F.
VIII- 4-1-2-2	Residence: (city and either US State, if applicable, or country)	San Diego, California
VIII- 4-1-2-3	Mailing address:	6254 Lakewood Street San Diego, CA 92122 United States of America San Diego California United States of America
VIII- 4-1-2-4	Citizenship:	US
VIII- 4-1-2-5	Inventor's Signature: (If not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	<i>D. F. Harvey</i> 14 Sept 2004
VIII- 4-1-2-6	Date (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	
VIII- 4-1-3-1	Name (LAST, First)	GSCHWEND, Heinz W.
VIII- 4-1-3-2	Residence: (city and either US State, if applicable, or country)	Santa Rosa, California
VIII- 4-1-3-3	Mailing address:	161 Meadowcroft Way Santa Rosa, CA 95403 United States of America Santa Rosa California United States of America
VIII- 4-1-3-4	Citizenship:	US
VIII- 4-1-3-5	Inventor's Signature: (If not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	<i>Heinz W. Gschwend</i>
VIII- 4-1-3-6	Date (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	Oct. 05, 2004